[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354268-105":59,"doc-detail-354268-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circulating-immune-cell-profiling-in-advanced-cervical-and-endometrial-cancer-patients-treated-with-pd-1-blockade-radiotherapy-and-immune-modulation-in-the-primmo-trial","Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade - radiotherapy, and immune modulation in the PRIMMO trial","","Immune checkpoint blockade (ICB) improves cancer therapy, yet durable benefit occurs only in patient subsets. This exploratory translational study used peripheral blood immune profiling to address the limitations of tissue biomarkers for tracking systemic immune dynamics in advanced cervical and endometrial cancer. Blood samples were collected at baseline, week 7, and post-treatment, then analyzed by multicolor flow cytometry and ELISA. Immune scores related to both response and survival, while non-responders showed sustained pDC decreases and increased activation and checkpoint marker expression across T-cell subsets and NK cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-immune-cell-profiling-in-advanced-cervical-and-endometrial-cancer-patients-treated-with-pd-1-blockade-radiotherapy-and-immune-modulation-in-the-primmo-trial/354268/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-immune-cell-profiling-in-advanced-cervical-and-endometrial-cancer-patients-treated-with-pd-1-blockade-radiotherapy-and-immune-modulation-in-the-primmo-trial/354268.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does the study focus on peripheral blood immune profiling instead of tissue biomarkers?","Question",{"text":112,"@type":113},"Tissue biomarkers can be invasive and cannot fully capture systemic immune changes. Peripheral blood provides a noninvasive way to study immune dynamics during treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patient samples collected and what assays were used?",{"text":117,"@type":113},"Peripheral blood was collected at inclusion (baseline), on-treatment (week 7), and post-treatment (week 26 or earlier if progression occurred). Immune subsets and systemic immune mediators were measured using multicolor flow cytometry and ELISA.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune features were associated with outcomes at baseline and during treatment?",{"text":121,"@type":113},"At baseline, CTLA-4+ PD-1+ CD4+ T cells and CD161+CD56+CD16+ NK cells related to survival outcomes, while a combined immune score linked to both response and survival. Responders showed relatively stable profiles, whereas non-responders had sustained pDC decreases and increased activation and checkpoint marker expression across T-cell subsets, with increased NK activation features.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354268,1790151367,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Original Research PUBLISHED 21 May 2026  \nDOI 10.3389/fimmu.2026.1794131  \nOPEN ACCESS  \nEDITED BY  \nMutlu Demiray,  \nMedicana Health Group, Türkiye  \nREVIEWED BY  \nMegha Das,  \nCentre for Cellular & Molecular Biology (CCMB), India  \nAllen Zhang,  \nUniversity of British Columbia, Canada  \n*CORRESPONDENCE  \nFre´ de´ric Amant  \n [frederic.amant@uzleuven.be](frederic.amant@uzleuven.be)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 22 January 2026  \nREVISED 24 April 2026  \nACCEPTED 05 May 2026  \nPUBLISHED 21 May 2026  \nCITATION  \nBaiden-Amissah REM, Tuyaerts S, Annibali D, Herreros-Pomares A, De Wispelaere W, Benedetto RM, De Jaeghere EA, Van Nuffel AMT, Vuylsteke P, Henry S, Bich Trinh X, Van Dam PA, Aspeslagh S, De Caluwe´ A, Naert E, Vandecasteele K, Denys HG and Amant F (2026) Circulating immune cell proﬁling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial. Front. Immunol. 17:1794131 .  \ndoi: 10.3389/fimmu.2026.1794131  \nCOPYRIGHT  \n© 2026 Baiden-Amissah, Tuyaerts, Annibali, Herreros-Pomares, De Wispelaere, Benedetto, De Jaeghere, Van Nuffel, Vuylsteke, Henry, Bich Trinh, Van Dam, Aspeslagh, De Caluwe´, Naert, Vandecasteele, Denys and Amant. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCirculating immune cell proﬁling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial  \nRegina Esi Mensimah Baiden-Amissah 1,2†, Sandra Tuyaerts 1,2,3,4†, Daniela Annibali 1,2,5, Alejandro Herreros-Pomares 1,2,  \nWout De Wispelaere 1,2, Rossana Maria Benedetto 1,  \nEmiel A. De Jaeghere 6,7, An M. T. Van Nuffel 8, Peter Vuylsteke 9, St´ephanie Henry 9, Xuan Bich Trinh 10,11,12, Peter A. Van Dam 10,11,12, Sandrine Aspeslagh 3, Alex De Caluw´e13,14, Eline Naert 6,7, Katrien Vandecasteele 7,15, Hannelore G. Denys 6,7  \nand Fr´ed´eric Amant 1,2,16,17*  \n1Gynecologic Oncology, Department of Oncology, Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium, 2 Leuven Cancer Institute, Leuven, Belgium, 3 Department of Medical Oncology, University Hospital Brussels, Brussels, Belgium, 4Translational Oncology Research Center (TORC), Vrije Universiteit Brussel, Brussels, Belgium, 5Gynecological Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands, 6 Department of Medical Oncology, Ghent University Hospital,  \nGhent, Belgium, 7Cancer Research Institute Ghent (CRIG), Ghent, Belgium, 8Anticancer Fund, Strombeek-Bever, Belgium, 9 Department of Hemato-Oncology, Centre Hospitalier Universitaire, Universite´ Catholique de Louvain Namur (Sainte-Elisabeth), Namur, Belgium, 10 Department of Gynecologic Oncology and Senology, University Hospital Antwerp, Edegem, Belgium, 11 Multidisciplinary Oncologic Centre Antwerp (MOCA), University Hospital Antwerp, Edegem, Belgium, 12Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Edegem, Belgium, 13 Université Libre de Bruxelles (ULB), Hôpitaux Universitaires de Bruxelles (H. U. B), Institut Jules Bordet, Brussels, Belgium, 14 Department of Radiation Oncology, General Hospital Sint-Maarten, Mechelen, Belgium, 15 Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium, 16Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam Medical Center, Amsterdam, Netherlands, 17 Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium  \nBackground: Immune checkpoint ","cbCaiiMtTdp61489","https://ap.wps.com/l/cbCaiiMtTdp61489","pdf",5445042,16,"English","# Background\n# Methods\n# Results","[{\"question\":\"Why does the study focus on peripheral blood immune profiling instead of tissue biomarkers?\",\"answer\":\"Tissue biomarkers can be invasive and cannot fully capture systemic immune changes. Peripheral blood provides a noninvasive way to study immune dynamics during treatment.\"},{\"question\":\"How were patient samples collected and what assays were used?\",\"answer\":\"Peripheral blood was collected at inclusion (baseline), on-treatment (week 7), and post-treatment (week 26 or earlier if progression occurred). Immune subsets and systemic immune mediators were measured using multicolor flow cytometry and ELISA.\"},{\"question\":\"What immune features were associated with outcomes at baseline and during treatment?\",\"answer\":\"At baseline, CTLA-4+ PD-1+ CD4+ T cells and CD161+CD56+CD16+ NK cells related to survival outcomes, while a combined immune score linked to both response and survival. Responders showed relatively stable profiles, whereas non-responders had sustained pDC decreases and increased activation and checkpoint marker expression across T-cell subsets, with increased NK activation features.\"}]","Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade - radiotherapy, and immune modulation in the PRIMMO trial | PDF",1790109781,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c25b6b8dc841a2d4223b86a9e2fbd23b.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8289c53b6a3557541ce8a411c391760e.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df4199b8c76cb3b280d73b735c0a572e.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b3107d7cf715220c6f07f3a843a0516.webp",980,1385]